TY - JOUR
T1 - Randomized dose-searching phase ILE/II trials of fractionation in radiation therapy for cancer
AU - Diener-west, Marie
AU - Pajak, Thomas F.
AU - Bauer, Madeline
AU - Cox, James D.
N1 - Funding Information:
Received February 11, 1991; revised April 17, 1991; accepted April 25, 1991. Supported by Public Health Service grants CA-32115 and CA-21661 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. M. Diener-West, The Johns Hopkins University, School of Hygiene and Public Health, Baltimore, Md. Formerly, Radiation Therapy Oncology Group, Statistical Unit, Philadelphia, Pa. T. F. Pajak, Radiation Therapy Oncology Group, Statistical Unit, Philadelphia, Pa. M. Bauer, Children's Cancer Study Group/University of Southern California, Arcadia, Calif. Formerly, Radiation Therapy Oncology Group, Statistical Unit, Philadelphia, Pa. J. D. Cox, University of Texas M.D. Anderson Cancer Center, Houston, Tex. We thank Ms. Evelyn Heinze for her technical assistance and Ms. Joanne Corish, Ms. Mary Murzyn, and Ms. Maritza Cedeno for typing the manuscript. *Correspondence to: Thomas F. Pajak, Ph.D., Radiation Therapy Oncology Group, Statistical Unit, 1101 Market St., Philadelphia, PA 19107.
PY - 1991/8/7
Y1 - 1991/8/7
N2 - This article describes a new design, phase ILE/II dose searching, used in four prospective, randomized, multicenter clinical trials of escalating total doses of hyperfractionated radiation. This design combines an experimental protocol with a statistical application of ranking and selection theory. Its purpose was to identify (within a certain margin of error) a dose that achieved the highest rate of clinical response from a set of doses that were tolerable in terms of both acute (within 90 days) and late (more than 90 days) toxic effects (LE). We calculated the number of patients required to reliably test toxicity under various assumptions. To determine the maximum tolerated total dose for hyperfractionated radiation, we randomly assigned patients with tumors that responded to radiation theraphy in a dose-dependent manner from four body sites (lung, upper respiratory and digestive tract, bladder, and brain) to one of three regimens total doses (D1, D2, or D3) differing by increments of 4.8 Gy. All patients received two fractions of 1.2 Gy each (separated by 4-6 hours) daily 5 days a week. The lowest total dose was set at the level considered tolerable with standard once-a-day radiation therapy. We tested tumor responses and late toxic effects of higher doses by assigning patients to these three regimens until acute effects and early estimates of late effects were found to be acceptable for the highest dose D3; thereafter, regimen D1 was closed, and additional patients were assigned to D2, D3 and D4 (an escalated total dose greater than D3 by an increment of 4.8 Gy). The assignment of patients was performed in a weighted manner (1:1:2), so that greater numbers were assigned to the highest dose regimen (whether D3 or D4) to allow rapid evaluation of the feasibility of the highest dose. [J Natl Cancer Inst 83:1065-1071, 1991]
AB - This article describes a new design, phase ILE/II dose searching, used in four prospective, randomized, multicenter clinical trials of escalating total doses of hyperfractionated radiation. This design combines an experimental protocol with a statistical application of ranking and selection theory. Its purpose was to identify (within a certain margin of error) a dose that achieved the highest rate of clinical response from a set of doses that were tolerable in terms of both acute (within 90 days) and late (more than 90 days) toxic effects (LE). We calculated the number of patients required to reliably test toxicity under various assumptions. To determine the maximum tolerated total dose for hyperfractionated radiation, we randomly assigned patients with tumors that responded to radiation theraphy in a dose-dependent manner from four body sites (lung, upper respiratory and digestive tract, bladder, and brain) to one of three regimens total doses (D1, D2, or D3) differing by increments of 4.8 Gy. All patients received two fractions of 1.2 Gy each (separated by 4-6 hours) daily 5 days a week. The lowest total dose was set at the level considered tolerable with standard once-a-day radiation therapy. We tested tumor responses and late toxic effects of higher doses by assigning patients to these three regimens until acute effects and early estimates of late effects were found to be acceptable for the highest dose D3; thereafter, regimen D1 was closed, and additional patients were assigned to D2, D3 and D4 (an escalated total dose greater than D3 by an increment of 4.8 Gy). The assignment of patients was performed in a weighted manner (1:1:2), so that greater numbers were assigned to the highest dose regimen (whether D3 or D4) to allow rapid evaluation of the feasibility of the highest dose. [J Natl Cancer Inst 83:1065-1071, 1991]
UR - http://www.scopus.com/inward/record.url?scp=0025744909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025744909&partnerID=8YFLogxK
U2 - 10.1093/jnci/83.15.1065
DO - 10.1093/jnci/83.15.1065
M3 - Article
C2 - 1875413
AN - SCOPUS:0025744909
VL - 83
SP - 1065
EP - 1071
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 15
ER -